Welcome to our dedicated page for Celularity news (Ticker: CELU), a resource for investors and traders seeking the latest updates and insights on Celularity stock.
Celularity Inc. reports developments in regenerative and cellular medicine, including longevity-focused programs, placental-derived cell therapies and commercial regenerative medicine products such as Biovance and Biovance 3L. Company news also covers clinical and coverage-related updates, operating and financial results, capital-structure actions and governance matters.
Recurring corporate updates include periodic-reporting status, Nasdaq compliance, tax-credit monetization, material agreements and shareholder matters. The company's disclosures also reference its common stock and warrants trading on Nasdaq under CELU and CELUW.
Celularity (Nasdaq: CELU) and MuseCell Innovations announced a U.S.-based manufacturing collaboration under which Celularity will establish production of Dezawa MuseCells (DMCs) at its 147,215-square-foot Florham Park, New Jersey facility. The initial program will set up manufacturing capability for MCI-authenticated DMC preparations from qualified perinatal, bone marrow and adipose sources using the licensed Dezawa Method and MCI’s product specifications.
The collaboration also covers DMC-derived products, including Dezawa MuseExosomes and Dezawa MuseSecretome, each with dedicated processes, analytical characterization and release criteria. Following the initial project, the parties intend to expand to additional products and programs. Based on current market conditions and its projections, MCI believes the expanded relationship could result in more than $300 million in aggregate purchases from Celularity over five years and is anticipated to generate more than 200 high-tech jobs at the Florham Park site while expanding MCI’s U.S. manufacturing network and preserving its quality, traceability and authentication framework.
Celularity (Nasdaq: CELU) reported that on August 21, 2026 it received a Nasdaq Listing Qualifications notice stating the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it has not filed its Form 10-Qs for quarters ended March 31 and June 30, 2026.
According to Celularity, Nasdaq has requested a compliance plan by September 4, 2026, and any exception would run no later than November 16, 2026. The notice has no immediate effect on the listing or trading of Celularity’s common stock, which continues on the Nasdaq Capital Market under the symbol CELU. The company is working to complete and file both quarterly reports as soon as practicable.
Celularity (Nasdaq: CELU) and Fountain Life announced that cenplacel-L, a placental-derived allogeneic investigational cell therapy, will be available for physician-directed investigational use in Florida under new regenerative medicine statutes effective July 1, 2025.
The partnership leverages Celularity’s FDA-registered, GMP-compliant facility and Fountain Life’s preventive, longevity-focused care model.
Celularity (Nasdaq: CELU) released a CEO letter outlining a sharper focus on placental-derived cellular therapies for longevity and age-related disease.
The company out-licensed its biomaterials business to NexGel for up to $30 million, eliminated nearly $13 million of recorded liabilities, highlighted growing physician demand for cenplacel-L, emphasized early commercial efforts in Florida with Fountain Life, and announced Rick Gonzalez as Chief Commercial Officer while acknowledging residual debt and capital constraints.
Celularity (Nasdaq: CELU) appointed Rick Gonzalez as Chief Commercial Officer, effective May 29, 2026. He will lead global commercialization of cenplacel-L, the Lifebank cellular banking platform and the broader regenerative medicine portfolio, reporting to CEO Robert J. Hariri.
Gonzalez brings 20+ years of biotech and medtech leadership, including roles at Alume Biosciences, Navidea Biopharmaceuticals and Spectrum Pharmaceuticals, where he previously helped drive significant revenue expansion. Celularity cites growing physician demand in permissive markets for cenplacel-L and ongoing 2025 Lifebank sales as drivers to strengthen commercial capabilities.
Celularity (Nasdaq: CELU) received a Nasdaq notice on May 27, 2026 for not timely filing its Form 10-Q for the quarter ended March 31, 2026, breaching Nasdaq Listing Rule 5250(c)(1). The notice does not immediately affect CELU’s Nasdaq Capital Market listing or trading.
Celularity has until July 28, 2026 to submit a compliance plan, and Nasdaq may grant up to 180 days from the Form 10-Q due date, to November 16, 2026. The company is working to file the report and expects to regain full reporting compliance.
Celularity (Nasdaq: CELU) filed its Annual Report on Form 10-K for fiscal 2025 on May 1, 2026 and has regained compliance with Nasdaq Listing Rule 5250(c)(1). The company said it completed strategic actions including an out-license of its biomaterials portfolio, a realignment of non-core personnel and a $13 million reduction in recorded liabilities. Management characterized the moves as sharpening strategic focus and strengthening the balance sheet to concentrate on core longevity and cell therapy platforms.
Celularity (Nasdaq: CELU) closed a transaction with NexGel on April 21, 2026, selling certain commercial and other assets from its biomaterials product portfolio.
Celularity received $13.3 million consideration: $8.3M cash at closing and a $5.0M convertible promissory note, plus up to $20.0M in milestone payments and royalties. The deal enabled retirement of nearly $13.0M of debt and aims to refocus resources on Celularity’s longevity therapeutic pipeline and manufacturing platform.
Celularity (Nasdaq: CELU) received a Nasdaq notice on April 16, 2026 for late filing of its Annual Report on Form 10-K for the fiscal year ended December 31, 2025.
The notice says the company is not currently compliant with Nasdaq Listing Rule 5250(c)(1), but trading of CELU and CELUW continues. Celularity has 60 days to submit a compliance plan and may receive up to 180 days if Nasdaq accepts the plan. The company is working to file the Form 10-K and currently expects to do so in the coming weeks, but offers no assurance it will regain compliance.
Celularity (Nasdaq: CELU) reiterated its strategic commercialization partnership with NEXGEL (Nasdaq: NXGL) to license established biomaterial products and three 510(k) pathway programs. Celularity will be the exclusive manufacturer at its FDA-compliant Florham Park, New Jersey facility.
The transaction is expected to close no later than April 15, 2026, subject to customary closing conditions, and aims to leverage renewed regulatory and reimbursement clarity for placental-derived biomaterials.